Treatment with 12B9m administered concurrently with ESA was more effective than 12B9m administered before or after ESA. (A) Experimental scheme detailing administration time of intraperitoneal BA (3 × 108 particles per mouse), intravenous Ab (5 mg per mouse), and intravenous ESA (300 µg/kg Epoetin alfa) in Hep1 mice. Potential Ab treatment times relative to ESA are indicated. Hb was monitored on either day 6 or day 7 as specified and used to assign mice to groups as in Figure 2. Hb was measured again at day 14 in all experiments (n = 5 mice per group). (B) Comparison of day 14 Hb response to 12B9m administration on day 6 (pretreatment) and day 8 (concurrent treatment) relative to ESA. (C) Comparison of day 14 Hb response to 12B9m administration on day 8 (concurrent treatment) and day 10 (posttreatment). Statistical comparisons against control Ab group are shown (1-way ANOVA with Dunnett’s post hoc test). *P < .05; **P < .01. All results are shown as mean ± SEM.
